The endocannabinoid system and sex steroid hormone-dependent cancers

International Journal of Endocrinology

Volumn 2013, Issue , 2013, Pages

  Ayakannu, Thangesweran ^a   Taylor, Anthony H ^a   Marczylo, Timothy H ^a   Willets, Jonathon M ^a   Konje, Justin C ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84893822143     PISSN: 16878337     EISSN: 16878345     Source Type: Journal    
DOI: 10.1155/2013/259676     Document Type: Review

References (164)

1. Kogan N. M., Mechoulam R., Cannabinoids in health and disease. Dialogues in Clinical Neuroscience 2007 9 4 413 430 2-s2.0-38849111946 (Pubitemid 351187565)
2. Guindon J., Hohmann A. G., The endocannabinoid system and cancer: therapeutic implication. British Journal of Pharmacology 2011 163 7 1447 1463 2-s2.0-79960336157 10.1111/j.1476-5381.2011.01327.x
3. Cota D., Woods S. C., The role of the endocannabinoid system in the regulation of energy homeostasis. Current Opinion in Endocrinology & Diabetes 2005 12 5 338 351 2-s2.0-26444539625 10.1097/01.med.0000178715.87999.69 (Pubitemid 41433815)
4. de Petrocellis L., Cascio M. G., di Marzo V., The endocannabinoid system: a general view and latest additions. British Journal of Pharmacology 2004 141 5 765 774 2-s2.0-1842611887 10.1038/sj.bjp.0705666 (Pubitemid 38446177)
5. Matsuda L. A., Lolait S. J., Brownstein M. J., Young A. C., Bonner T. I., Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990 346 6284 561 564 2-s2.0-0025325535 10.1038/346561a0 (Pubitemid 20238806)
6. 1 receptor knockout mice. Science 1999 283 5400 401 404 2-s2.0-0033555839 10.1126/science.283.5400.401 (Pubitemid 29045294)
7. 1 receptor knockout mice. Proceedings of the National Academy of Sciences of the United States of America 1999 96 10 5780 5785 2-s2.0-0033545866 10.1073/pnas.96.10.5780 (Pubitemid 29234695)
8. Munro S., Thomas K. L., Abu-Shaar M., Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993 365 6441 61 65 2-s2.0-0027515373 10.1038/365061a0 (Pubitemid 23305569)
9. 2 receptor. European Journal of Pharmacology 2000 396 2-3 141 149 2-s2.0-0034685707 10.1016/S0014-2999(00)00211- 9 (Pubitemid 30265571)
10. Bifulco M., di Marzo V., Targeting the endocannabinoid system in cancer therapy: a call for further research. Nature Medicine 2002 8 6 547 550 2-s2.0-0036278032 10.1038/nm0602-547 (Pubitemid 34633419)
11. Galve-Roperh I., Sánchez C., Cortés M. L., del Pulgar T. G., Izquierdo M., Guzmán M., Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nature Medicine 2000 6 3 313 319 2-s2.0-17344380844 10.1038/73171 (Pubitemid 30148624)
12. Cianchi F., Papucci L., Schiavone N., Lulli M., Magnelli L., Vinci M. C., Messerini L., Manera C., Ronconi E., Romagnani P., Donnini M., Perigli G., Trallori G., Tanganelli E., Capaccioli S., Masini E., Cannabinoid receptor activation induces apoptosis through tumor necrosis factor α -mediated ceramide de novo synthesis in colon cancer cells. Clinical Cancer Research 2008 14 23 7691 7700 2-s2.0-59449111015 10.1158/1078-0432.CCR-08-0799
13. Piomelli D., Giuffrida A., Calignano A., Rodríguez De Fonseca F., The endocannabinoid system as a target for therapeutic drugs. Trends in Pharmacological Sciences 2000 21 6 218 224 2-s2.0-0034212295 10.1016/S0165-6147(00)01482-6 (Pubitemid 30331091)
14. Maccarrone M., van der Stelt M., Rossi A., Veldink G. A., Vliegenthart J. F. G., Agrò A. F., Anandamide hydrolysis by human cells in culture and brain. Journal of Biological Chemistry 1999 273 48 32332 32339 2-s2.0-0033610794 10.1074/jbc.273.48.32332
15. Devane W. A., Hanus L., Breuer A., Pertwee R. G., Stevenson L. A., Griffin G., Gibson D., Mandelbaum A., Etinger A., Mechoulam R., Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992 258 5090 1946 1949 2-s2.0-0027078685 (Pubitemid 23026736)
16. Mechoulam R., Ben-Shabat S., Hanuš L., Ligumsky M., Kaminski N. E., Schatz A. R., Gopher A., Almog S., Martin B. R., Compton D. R., Pertwee R. G., Griffin G., Bayewitch M., Barg J., Vogel Z., Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochemical Pharmacology 1995 50 1 83 90 2-s2.0-0029012014 10.1016/0006-2952(95) 00109-D
17. Pertwee R. G., Pharmacological actions of cannabinoids. Handbook of Experimental Pharmacology 2005 168 1 51 2-s2.0-31144449705
18. Piomelli D., The molecular logic of endocannabinoid signalling. Nature Reviews Neuroscience 2003 4 11 873 884 2-s2.0-0242268553 10.1038/nrn1247 (Pubitemid 37351427)
19. Matias I., di Marzo V., Endocannabinoid synthesis and degradation, and their regulation in the framework of energy balance. Journal of Endocrinological Investigation 2006 29 supplement 3 15 26 2-s2.0-33745487912
20. di Marzo V., Fontana A., Cadas H., Schinelli S., Cimino G., Schwartz J.-C., Piomelli D., Formation and inactivation of endogenous cannabinoid anandanide in central neurons. Nature 1994 372 6507 686 691 2-s2.0-0028589390
21. Okamoto Y., Morishita J., Tsuboi K., Tonai T., Ueda N., Molecular characterization of a phospholipase D generating anandamide and its congeners. Journal of Biological Chemistry 2004 279 7 5298 5305 2-s2.0-1242294480 10.1074/jbc.M306642200 (Pubitemid 38220550)
22. Prescott S. M., Majerus P. W., Characterization of 1,2-diacylglycerol hydrolysis in human platelets. Demonstration of an arachidonoyl-monoacylglycerol intermediate. Journal of Biological Chemistry 1983 258 2 764 769 2-s2.0-0020659765 (Pubitemid 13139323)
23. McFarland M. J., Barker E. L., Anandamide transport. Pharmacology & Therapeutics 2004 104 2 117 135 2-s2.0-7044270770 10.1016/j.pharmthera.2004.07. 008 (Pubitemid 39424256)
24. Cravatt B. F., Giang D. K., Mayfield S. P., Boger D. L., Lerner R. A., Gilula N. B., Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 1996 384 6604 83 87 2-s2.0-0029904838 10.1038/384083a0 (Pubitemid 26374593)
25. di Marzo V., Bisogno T., Sugiura T., Melck D., de Petrocellis L., The novel endogenous cannabinoid 2-arachidonoylglycerol is inactivated by neuronal- and basophil-like cells: connections with anandamide. Biochemical Journal 1998 331 part 1 15 19 2-s2.0-0032055496 (Pubitemid 28163951)
26. Goparaju S. K., Ueda N., Taniguchi K., Yamamoto S., Enzymes of porcine brain hydrolyzing 2-arachidonoylglycerol, an endogenous ligand of cannabinoid receptors. Biochemical Pharmacology 1999 57 4 417 423 2-s2.0-0032898720 10.1016/S0006-2952(98)00314-1 (Pubitemid 29065290)
27. Fu J., Bottegoni G., Sasso O., Bertorelli R., Rocchia W., Masetti M., Guijarro A., Lodola A., Armirotti A., Garau G., Bandiera T., Reggiani A., Mor M., Cavalli A., Piomelli D., A catalytically silent FAAH-1 variant drives anandamide transport in neurons. Nature Neuroscience 2012 15 1 64 69 2-s2.0-84555198880 10.1038/nn.2986
28. 1 cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochemical Journal 2000 351 part 3 817 824 2-s2.0-0034332637 10.1042/0264-6021:3510817
29. 1 receptor. Journal of Pharmacology and Experimental Therapeutics 2002 301 3 1020 1024 2-s2.0-0036260823 10.1124/jpet.301.3.1020 (Pubitemid 34595094)
30. di Marzo V., 'Endocannabinoids' and other fatty acid derivatives with cannabimimetic properties: biochemistry and possible physiopathological relevance. Biochimica et Biophysica Acta 1998 1392 2-3 153 175 2-s2.0-0031834745 10.1016/S0005-2760(98)00042-3 (Pubitemid 28287321)
31. Maccarrone M., Finazzi-Agró A., Endocannabinoids and their actions. Vitamins and Hormones 2002 65 225 255 2-s2.0-0036044615 (Pubitemid 135763177)
32. Katayama K., Ueda N., Kurahashi Y., Suzuki H., Yamamoto S., Kato I., Distribution of anandamide amidohydrolase in rat tissues with special reference to small intestine. Biochimica et Biophysica Acta 1997 1347 2-3 212 218 2-s2.0-0001048154 10.1016/S0005-2760(97)00078-7 (Pubitemid 27368114)
33. Ben-Shabat S., Fride E., Sheskin T., Tamiri T., Rhee M.-H., Vogel Z., Bisogno T., de Petrocellis L., di Marzo V., Mechoulam R., An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. European Journal of Pharmacology 1998 353 1 23 31 2-s2.0-0031830516 10.1016/S0014-2999(98)00392-6 (Pubitemid 28352285)
34. Bornheim L. M., Kim K. Y., Chen B., Correia M. A., Microsomal cytochrome P450-medited liver and brain anandamide metabolism. Biochemical Pharmacology 1995 50 5 677 686 2-s2.0-0028978057 10.1016/0006-2952(95)00177-2
35. Bornheim L. M., Everhart E. T., Li J., Correia M. A., Characterization of cannabidiol-mediated cytochrome P450 inactivation. Biochemical Pharmacology 1993 45 6 1323 1331 2-s2.0-0027401508 10.1016/0006-2952(93)90286-6 (Pubitemid 23098331)
36. Edgemond W. S., Hillard C. J., Falck J. R., Kearn C. S., Campbell W. B., Human platelets and polymorphonuclear leukocytes synthesize oxygenated derivatives of arachidonylethanolamide (anandamide): their affinities for cannabinoid receptors and pathways of inactivation. Molecular Pharmacology 1998 54 1 180 188 2-s2.0-0031820286 (Pubitemid 28337601)
37. Kozak K. R., Marnett L. J., Oxidative metabolism of endocannabinoids. Prostaglandins Leukotrienes and Essential Fatty Acids 2002 66 2-3 211 220 2-s2.0-0036019390 10.1054/plef.2001.0359 (Pubitemid 34743596)
38. Yu M., Ives D., Ramesha C. S., Synthesis of prostaglandin E2 ethanolamide from anandamide by cyclooxygenase-2. Journal of Biological Chemistry 1997 272 34 21181 21186 2-s2.0-0030611859 10.1074/jbc.272.34.21181 (Pubitemid 27373979)
39. Kozak K. R., Rowlinson S. W., Marnett L. J., Oxygenation of the endocannabinoid, 2-arachidonylglycerol, to glyceryl prostaglandins by cyclooxygenase-2. Journal of Biological Chemistry 2000 275 43 33744 33749 2-s2.0-0034721794 10.1074/jbc.M007088200
40. Kozak K. R., Crews B. C., Ray J. L., Tai H.-H., Morrow J. D., Marnett L. J., Metabolism of prostaglandin glycerol esters and prostaglandin ethanolamides in vitro and in vivo. Journal of Biological Chemistry 2001 276 40 36993 36998 2-s2.0-0035813139 10.1074/jbc.M105854200
41. Fürstenberger G., Krieg P., Müller-Decker K., Habenicht A. J. R., What are cyclooxygenases and lipoxygenases doing in the driver's seat of carcinogenesis? International Journal of Cancer 2006 119 10 2247 2254 2-s2.0-33749612562 10.1002/ijc.22153 (Pubitemid 44546942)
42. Wang J., Ueda N., Role of the endocannabinoid system in metabolic control. Current Opinion in Nephrology and Hypertension 2008 17 1 1 10 2-s2.0-37349023167 10.1097/MNH.0b013e3282f29071 (Pubitemid 350295190)
43. Mailleux P., Parmentier M., Vanderhaeghen J.-J., Distribution of cannabinoid receptor messenger RNA in the human brain: an in situ hybridization histochemistry with oligonucleotides. Neuroscience Letters 1992 143 1-2 200 204 2-s2.0-0026670687
44. Glass M., Dragunow M., Faull R. L. M., Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 1997 77 2 299 318 2-s2.0-0031047273 10.1016/S0306-4522(96)00428-9 (Pubitemid 27079604)
45. 2 receptors: immunohistochemical localization in rat brain. Brain Research 2006 1071 1 10 23 2-s2.0-32844465920 10.1016/j.brainres.2005.11.035 (Pubitemid 43255471)
46. Pacher P., Bátkai S., Kunos G., The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacological Reviews 2006 58 3 389 462 2-s2.0-33748703859 10.1124/pr.58.3.2 (Pubitemid 44394908)
47. Basavarajappa B. S., Neuropharmacology of the endocannabinoid signaling system-molecular mechanisms, biological actions and synaptic plasticity. Current Neuropharmacology 2007 5 2 81 97 2-s2.0-34347375273 10.2174/157015907780866910 (Pubitemid 47019423)
48. Gerard C. M., Mollereau C., Vassart G., Parmentier M., Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochemical Journal 1991 279 part 1 129 134 2-s2.0-0025878961
49. Bouaboula M., Rinaldi M., Carayon P., Carillon C., Delpech B., Shire D., Le Fur G., Casellas P., Cannabinoid-receptor expression in human leukocytes. European Journal of Biochemistry 1993 214 1 173 180 2-s2.0-0027215426 (Pubitemid 23168532)
50. 1 cannabinoid receptors in human vascular endothelial cells. Biochemical Journal 2000 346 part 3 835 840 2-s2.0-0034653517 10.1042/0264-6021:3460835 (Pubitemid 30171048)
51. 1 cannabinoid receptor mRNA and protein. The European Journal of Neuroscience 2000 12 3 1123 1127 2-s2.0-0034025978 10.1046/j.1460-9568.2000.01027.x (Pubitemid 30168791)
52. Pagotto U., Marsicano G., Fezza F., Theodoropoulou M., Grübler Y., Stalla J., Arzberger T., Milone A., Losa M., di Marzo V., Lutz B., Stalla G. K., Normal human pituitary gland and pituitary adenomas express cannabinoid receptor type 1 and synthesize endogenous cannabinoids: first evidence for a direct role of cannabinoids on hormone modulation at the human pituitary level. Journal of Clinical Endocrinology and Metabolism 2001 86 6 2687 2696 2-s2.0-17844379461 10.1210/jc.86.6.2687 (Pubitemid 32545724)
53. Bifulco M., Laezza C., Pisanti S., Gazzerro P., Cannabinoids and cancer: pros and cons of an antitumour strategy. British Journal of Pharmacology 2006 148 2 123 135 2-s2.0-33745013193 10.1038/sj.bjp.0706632 (Pubitemid 43873031)
54. El-Talatini M. R., Taylor A. H., Elson J. C., Brown L., Davidson A. C., Konje J. C., Localisation and function of the endocannabinoid system in the human ovary. PLoS ONE 2009 4 2 2-s2.0-61449237396 10.1371/journal.pone.0004579 e4579
55. Lutz B., Molecular biology of cannabinoid receptors. Prostaglandins Leukotrienes and Essential Fatty Acids 2002 66 2-3 123 142 2-s2.0-0036019383 10.1054/plef.2001.0342 (Pubitemid 34743590)
56. Begg M., Pacher P., Bátkai S., Osei-Hyiaman D., Offertáler L., Fong M. M., Liu J., Kunos G., Evidence for novel cannabinoid receptors. Pharmacology & Therapeutics 2005 106 2 133 145 2-s2.0-18144385088 10.1016/j.pharmthera.2004.11.005 (Pubitemid 40613055)
57. Mackie K., Stella N., Cannabinoid receptors and endocannabinoids: evidence for new players. The AAPS Journal 2006 8 2, article 34 E298 E306 2-s2.0-33646814424 10.1208/aapsj080234
58. Godlewski G., Offertáler L., Wagner J. A., Kunos G., Receptors for acylethanolamides-GPR55 and GPR119. Prostaglandins & Other Lipid Mediators 2009 89 3-4 105 111 2-s2.0-69549130581 10.1016/j.prostaglandins.2009.07.001
59. Mackie K., Hille B., Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proceedings of the National Academy of Sciences of the United States of America 1992 89 9 3825 3829 2-s2.0-0026603679
60. 2+ channel current. American Journal of Physiology: Heart and Circulatory Physiology 1999 276 6, part 2 H2085 H2093 2-s2.0-0033002210 (Pubitemid 29323495)
61. Mackie K., Lai Y., Westenbroek R., Mitchell R., Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. Journal of Neuroscience 1995 15 10 6552 6561 2-s2.0-0028823316
62. Huang S. M., Bisogno T., Trevisani M., Al-Hayani A., de Petrocellis L., Fezza F., Tognetto M., Petros T. J., Krey J. F., Chu C. J., Miller J. D., Davies S. N., Geppetti P., Walker J. M., di Marzo V., An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proceedings of the National Academy of Sciences of the United States of America 2002 99 12 8400 8405 2-s2.0-0037062411 10.1073/pnas.122196999 (Pubitemid 34651064)
63. Pistis M., Melis M., From surface to nuclear receptors: the endocannabinoid family extends its assets. Current Medicinal Chemistry 2010 17 14 1450 1467 2-s2.0-77950634824 10.2174/092986710790980014
64. Hall W., Christie M., Currow D., Cannabinoids and cancer: causation, remediation, and palliation. The Lancet Oncology 2005 6 1 35 42 2-s2.0-11944262124 10.1016/S1470-2045(04)01711-5 (Pubitemid 40100410)
65. del Pulgar T. G., Velasco G., Sánchez C., Haro A., Guzmán M., De novo-synthesized ceramide is involved in cannabinoid-induced apoptosis. Biochemical Journal 2002 363 part 1 183 188 2-s2.0-0036534724 10.1042/0264-6021:3630183 (Pubitemid 34280625)
66. 2 cannabinoid receptor. Cancer Research 2001 61 15 5784 5789 2-s2.0-0035422139 (Pubitemid 32769095)
67. de Petrocellis L., Melck D., Palmisano A., Bisogno T., Laezza C., Bifulco M., di Marzo V., The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proceedings of the National Academy of Sciences of the United States of America 1998 95 14 8375 8380 2-s2.0-0032493378 10.1073/pnas.95.14.8375 (Pubitemid 28326120)
68. Melck D., Rueda D., Galve-Roperh I., de Petrocellis L., Guzmán M., di Marzo V., Involvement of the cAMP/protein kinase A pathway and of mitogen- activated protein kinase in the anti-proliferative effects of anandamide in human breast cancer cells. FEBS Letters 1999 463 3 235 240 2-s2.0-0033405883 10.1016/S0014-5793(99)01639-7 (Pubitemid 30001925)
69. Melck D., de Petrocellis L., Orlando P., Bisogno T., Laezza C., Bifulco M., Marzo V. D. I., Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Endocrinology 2000 141 1 118 126 2-s2.0-0034465259 10.1210/en.141.1.118 (Pubitemid 32260350)
70. Llanos Casanova M., Blázquez C., Martínez-Palacio J., Villanueva C., Fernández-Aceñero M. J., Huffman J. W., Jorcano J. L., Guzmán M., Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. Journal of Clinical Investigation 2003 111 1 43 50 2-s2.0-0037253496 10.1172/JCI200316116 (Pubitemid 36134847)
71. Blázquez C., Casanova M. L., Planas A., del Pulgar T. G., Villanueva C., Fernández-Aceñero M. J., Aragonés J., Huffman J. W., Jorcano J. L., Guzmán M., Inhibition of tumor angiogenesis by cannabinoids. FASEB Journal 2003 17 3 529 531 2-s2.0-0037365941
72. 1 receptor stimulation on tumor growth and metastatic spreading: actions on signals involved in angiogenesis and metastasis. FASEB Journal 2003 17 12 1771 1773 2-s2.0-0141594998
73. Blázquez C., Carracedo A., Barrado L., Real P. J., Fernández-Luna J. L., Velasco G., Malumbres M., Guzmán M., Cannabinoid receptors as novel targets for the treatment of melanoma. FASEB Journal 2006 20 14 2633 2635 2-s2.0-39049190337 10.1096/fj.06-6638fje (Pubitemid 44953804)
74. Allister S. D., Chan C., Taft R. J., Luu T., Abood M. E., Moore D. H., Aldape K., Yount G., Cannabinoids selectively inhibit proliferation and induce death of cultured human glioblastoma multiforme cells. Journal of Neuro-Oncology 2005 74 1 31 40 2-s2.0-23944437209 10.1007/s11060-004-5950-2 (Pubitemid 41194527)
75. Bifulco M., Laezza C., Portella G., Vitale M., Orlando P., de Petrocellis L., di Marzo V., Control by the endogenous cannabinoid system of ras oncogene-dependent tumor growth. FASEB Journal 2001 15 14 2745 2747 2-s2.0-0035651034
76. Carracedo A., Gironella M., Lorente M., Garcia S., Guzmán M., Velasco G., Iovanna J. L., Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes. Cancer Research 2006 66 13 6748 6755 2-s2.0-33746138649 10.1158/0008-5472.CAN-06-0169 (Pubitemid 44085633)
77. Gustafsson K., Christensson B., Sander B., Flygare J., Cannabinoid receptor-mediated apoptosis induced by R (+)-methanandamide and Win55,212-2 is associated with ceramide accumulation and p38 activation in mantle cell lymphoma. Molecular Pharmacology 2006 70 5 1612 1620 2-s2.0-33751198532 10.1124/mol.106.025981
78. Sarfaraz S., Afaq F., Adhami V. M., Mukhtar H., Cannabinoid receptor as a novel target for the treatment of prostate cancer. Cancer Research 2005 65 5 1635 1641 2-s2.0-16444375370 10.1158/0008-5472.CAN-04-3410 (Pubitemid 40478586)
79. Caffarel M. M., Sarrió D., Palacios J., Guzmán M., Sánchez C., Δ9-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation. Cancer Research 2006 66 13 6615 6621 2-s2.0-33746125474 10.1158/0008-5472.CAN-05-4566 (Pubitemid 44085617)
80. Islam T. C., Asplund A. C., Lindvall J. M., Nygren L., Liden J., Kimby E., Christensson B., Smith C. I. E., Sander B., High level cannabinoid receptor 1, resistance of regulator G protein signaling 13 and differential expression of Cyclin D1 in mantle cell lymphoma. Leukemia 2003 17 9 1880 1890 2-s2.0-0141613823 10.1038/sj.leu.2403057 (Pubitemid 37185266)
81. Ek S., Högerkorp C.-M., Dictor M., Ehinger M., Borrebaeck C. A. K., Mantle cell lymphomas express a distinct genetic signature affecting lymphocyte trafficking and growth regulation as compared with subpopulations of normal human B cells. Cancer Research 2002 62 15 4398 4405 2-s2.0-0036682308 (Pubitemid 34827299)
82. Pulgar T. G. D., de Ceballos M. L., Guzmán M., Velasco G., Cannabinoids protect astrocytes from ceramide-induced apoptosis through the phosphatidylinositol 3-kinase/protein kinase B pathway. Journal of Biological Chemistry 2002 277 39 36527 36533 2-s2.0-0037184060 10.1074/jbc.M205797200
83. Carracedo A., Geelen M. J. H., Diez M., Hanada K., Guzmán M., Velasco G., Ceramide sensitizes astrocytes to oxidative stress: protective role of cannabinoids. Biochemical Journal 2004 380 part 2 435 440 2-s2.0-2942729530 10.1042/BJ20031714 (Pubitemid 38788115)
84. Molina-Holgado E., Vela J. M., Arévalo-Martín A., Almazán G., Molina-Holgado F., Borrell J., Guaza C., Cannabinoids promote oligodendrocyte progenitor survival: involvement of cannabinoid receptors and phosphatidylinositol-3 kinase/Akt signaling. Journal of Neuroscience 2002 22 22 9742 9753 2-s2.0-0037111841 (Pubitemid 35332857)
85. Sánchez C., Galve-Roperh I., Canova C., Brachet P., Guzmán M., Δ9-tetrahydrocannabinol induces apoptosis in C6 glioma cells. FEBS Letters 1998 436 1 6 10 2-s2.0-0032566430 10.1016/S0014-5793(98)01085-0 (Pubitemid 28454597)
86. Schmid P. C., Wold L. E., Krebsbach R. J., Berdyshev E. V., Schmid H. H. O., Anandamide and other N-acylethanolamines in human tumors. Lipids 2002 37 9 907 912 2-s2.0-0036756716 (Pubitemid 35332930)
87. Nithipatikom K., Endsley M. P., Isbell M. A., Falck J. R., Iwamoto Y., Hillard C. J., Campbell W. B., 2-arachidonoylglycerol: a novel inhibitor of androgen-independent prostate cancer cell invasion. Cancer Research 2004 64 24 8826 8830 2-s2.0-10844265493 10.1158/0008-5472.CAN-04-3136 (Pubitemid 39665485)
88. Endsley M. P., Thill R., Choudhry I., Williams C. L., Kajdacsy-Balla A., Campbell W. B., Nithipatikom K., Expression and function of fatty acid amide hydrolase in prostate cancer. International Journal of Cancer 2008 123 6 1318 1326 2-s2.0-49749120682 10.1002/ijc.23674
89. Nomura D. K., Long J. Z., Niessen S., Hoover H. S., Ng S.-W., Cravatt B. F., Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell 2010 140 1 49 61 2-s2.0-73149109062 10.1016/j.cell.2009.11. 027
90. Ligresti A., Bisogno T., Matias I., de Petrocellis L., Cascio M. G., Cosenza V., D'Argenio G., Scaglione G., Bifulco M., Sorrentini I., di Marzo V., Possible endocannabinoid control of colorectal cancer growth. Gastroenterology 2003 125 3 677 687 2-s2.0-0042972716 10.1016/S0016-5085(03)00881-3 (Pubitemid 37070686)
91. Michalski C. W., Oti F. E., Erkan M., Sauliunaite D., Bergmann F., Pacher P., Batkai S., Müller M. W., Giese N. A., Friess H., Kleeff J., Cannabinoids in pancreatic cancer: correlation with survival and pain. International Journal of Cancer 2008 122 4 742 750 2-s2.0-38349060681 10.1002/ijc.23114
92. 2 correlates with improved prognosis of patients with hepatocellular carcinoma. Cancer Genetics and Cytogenetics 2006 171 1 31 38 2-s2.0-33750298256 10.1016/j.cancergencyto.2006.06.014 (Pubitemid 44635750)
93. 2 frequently expressed on AML blasts, either induces a neutrophilic differentiation block or confers abnormal migration properties in a ligand-dependent manner. Blood 2004 104 2 526 534 2-s2.0-3142619136 10.1182/blood-2003-12-4357 (Pubitemid 38900037)
94. Held-Feindt J., Dörner L., Sahan G., Mehdorn H. M., Mentlein R., Cannabinoid receptors in human astroglial tumors. Journal of Neurochemistry 2006 98 3 886 893 2-s2.0-33745874094 10.1111/j.1471-4159.2006.03911.x (Pubitemid 44051288)
95. Calatozzolo C., Salmaggi A., Pollo B., Sciacca F. L., Lorenzetti M., Franzini A., Boiardi A., Broggi G., Marras C., Expression of cannabinoid receptors and neurotrophins in human gliomas. Neurological Sciences 2007 28 6 304 310 2-s2.0-38049025796 10.1007/s10072-007-0843-8
96. Gustafsson S. B., Lindgren T., Jonsson M., Jacobsson S. O. P., Cannabinoid receptor-independent cytotoxic effects of cannabinoids in human colorectal carcinoma cells: synergism with 5-fluorouracil. Cancer Chemotherapy and Pharmacology 2009 63 4 691 701 2-s2.0-58849113520 10.1007/s00280-008-0788-5
97. Wang D., Wang H., Ning W., Backlund M. G., Dey S. K., DuBois R. N., Loss of cannabinoid receptor 1 accelerates intestinal tumor growth. Cancer Research 2008 68 15 6468 6476 2-s2.0-51049102995 10.1158/0008-5472.CAN-08-0896
98. Ramer R., Hinz B., Inhibition of cancer cell invasion by cannabinoids via increased expression of tissue inhibitor of matrix metalloproteinases-1. Journal of the National Cancer Institute 2008 100 1 59 69 2-s2.0-38049185265 10.1093/jnci/djm268 (Pubitemid 351767340)
99. Czifra G., Varga A., Nyeste K., Marincsák R., Tóth B. I., Kovács I., Kovács L., Bíró T., Increased expressions of cannabinoid receptor-1 and transient receptor potential vanilloid-1 in human prostate carcinoma. Journal of Cancer Research and Clinical Oncology 2009 135 4 507 514 2-s2.0-61449211120 10.1007/s00432-008-0482-3
100. 1 receptor immunoreactivity is associated with disease severity and outcome in prostate cancer. European Journal of Cancer 2009 45 1 174 182 2-s2.0-57649242673 10.1016/j.ejca.2008.10.010
101. Börner C., Höllt V., Sebald W., Kraus J., Transcriptional regulation of the cannabinoid receptor type 1 gene in T cells by cannabinoids. Journal of Leukocyte Biology 2007 81 1 336 343 2-s2.0-33845863911 10.1189/jlb.0306224 (Pubitemid 46021284)
102. Rousseaux C., Thuru X., Gelot A., Barnich N., Neut C., Dubuquoy L., Dubuquoy C., Merour E., Geboes K., Chamaillard M., Ouwehand A., Leyer G., Carcano D., Colombel J.-F., Ardid D., Desreumaux P., Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nature Medicine 2007 13 1 35 37 2-s2.0-33846100339 10.1038/nm1521 (Pubitemid 46067383)
103. 1 receptor in human colon cancer cell lines. Scandinavian Journal of Gastroenterology 2008 43 1 66 72 2-s2.0-37549064372 10.1080/00365520701559011
104. Begum S., Emami N., Cheung A., Wilkins O., Der S., Hamel P. A., Cell-type-specific regulation of distinct sets of gene targets by Pax3 and Pax3/FKHR. Oncogene 2005 24 11 1860 1872 10.1038/sj.onc.1208315 (Pubitemid 40462788)
105. 1 receptor. FEBS Letters 2005 579 1 259 264 2-s2.0-11144263163 10.1016/j.febslet.2004.11.085 (Pubitemid 40023406)
106. Maccarrone M., Valensise H., Bari M., Lazzarin N., Romanini C., Finazzi-Agrò A., Progesterone up-regulates anandamide hydrolase in human lymphocytes: role of cytokines and implications for fertility. Journal of Immunology 2001 166 12 7183 7189 2-s2.0-0035877059 (Pubitemid 32525591)
107. Maccarrone M., Bari M., di Rienzo M., Finazzi-Agrò A., Rossi A., Progesterone activates Fatty Acid Amide Hydrolase (FAAH) promoter in human T lymphocytes through the transcription factor Ikaros: evidence for a synergistic effect of leptin. Journal of Biological Chemistry 2003 278 35 32726 32732 2-s2.0-0041856520 10.1074/jbc.M302123200 (Pubitemid 37055712)
108. Maccarrone M., Bisogno T., Valensise H., Lazzarin N., Fezza F., Manna C., di Marzo V., Finazzi-Agrò A., Low fatty acid amide hydrolase and high anandamide levels are associated with failure to achieve an ongoing pregnancy after IVF and embryo transfer. Molecular Human Reproduction 2002 8 2 188 195 2-s2.0-0036172276 (Pubitemid 34144978)
109. Rebollo A., Schmitt C., Ikaros, aiolos and helios: transcription regulators and lymphoid malignancies. Immunology & Cell Biology 2003 81 3 171 175 2-s2.0-0038356318 10.1046/j.1440-1711.2003.01159.x (Pubitemid 36649262)
110. Maccarrone M., Gasperi V., Fezza F., Finazzi-Agrò A., Rossi A., Differential regulation of fatty acid amide hydrolase promoter in human immune cells and neuronal cells by leptin and progesterone. European Journal of Biochemistry 2004 271 23-24 4666 4676 2-s2.0-11244306367 10.1111/j.1432-1033. 2004.04427.x (Pubitemid 40065570)
111. Guo Y., Wang H., Okamoto Y., Ueda N., Kingsley P. J., Marnett L. J., Schmid H. H. O., Das S. K., Dey S. K., N-acylphosphatidylethanolamine- hydrolyzing phospholipase D is an important determinant of uterine anandamide levels during implantation. Journal of Biological Chemistry 2005 280 25 23429 23432 2-s2.0-21244465211 10.1074/jbc.C500168200 (Pubitemid 40884817)
112. Maccarrone M., de Felici M., Bari M., Klinger F., Siracusa G., Finazzi-Agrò A., Down-regulation of anandamide hydrolase in mouse uterus by sex hormones. European Journal of Biochemistry 2000 267 10 2991 2997 2-s2.0-0008894432 10.1046/j.1432-1327.2000.01316.x (Pubitemid 30321346)
113. Ribeiro M. L., Vercelli C. A., Sordelli M. S., Farina M. G., Cervini M., Billi S., Franchi A. M., 17 β -oestradiol and progesterone regulate anandamide synthesis in the rat uterus. Reproductive BioMedicine Online 2009 18 2 209 218 2-s2.0-60549095607
114. 2) receptor agonists on luteal weight, circulating progesterone, luteal mRNA for luteinizing hormone (LH) receptors, and luteal unoccupied and occupied receptors for LH in vivo in ewes. Prostaglandins & Other Lipid Mediators 2011 94 1-2 17 24 2-s2.0-79551507599 10.1016/j.prostaglandins.2010.11.002
115. Habayeb O. M. H., Bell S. C., Konje J. C., Endogenous cannabinoids: metabolism and their role in reproduction. Life Sciences 2002 70 17 1963 1977 2-s2.0-0037087221 10.1016/S0024-3205(01)01539-9 (Pubitemid 34215122)
116. Shrivastava A., Kuzontkoski P. M., Groopman J. E., Prasad A., Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy. Molecular Cancer Therapeutics 2011 10 7 1161 1172 2-s2.0-79960115996 10.1158/1535-7163.MCT-10-1100
117. Karasu T., Marczylo T. H., Maccarrone M., Konje J. C., The role of sex steroid hormones, cytokines and the endocannabinoid system in female fertility. Human Reproduction Update 2011 17 3 347 361 2-s2.0-79954495409 10.1093/humupd/dmq058
118. Maccarrone M., Bari M., Battista N., Finazzi-Agrò A., Estrogen stimulates arachidonoylethanolamide release from human endothelial cells and platelet activation. Blood 2002 100 12 4040 4048 2-s2.0-0036891996 10.1182/blood-2002-05-1444 (Pubitemid 35396871)
119. Maccarrone M., Falciglia K., di Rienzo M., Finazzi-Agrò A., Endocannabinoids, hormone-cytokine networks and human fertility. Prostaglandins Leukotrienes and Essential Fatty Acids 2002 66 2-3 309 317 2-s2.0-0036019416 10.1054/plef.2001.0354 (Pubitemid 34743604)
120. Bloch E., Thysen B., Morrill G. A., Gardner E., Fujimoto G., Effects of cannabinoids on reproduction and development. Vitamins and Hormones 1979 36 203 258 2-s2.0-0018113146 10.1016/S0083-6729(08)60985-1
121. 1 receptor mRNA levels and immunoreactivity in pituitary hyperplasia induced by prolonged exposure to estrogens. Pituitary 2000 3 4 221 226 2-s2.0-0034353767 10.1023/A:1012874029689 (Pubitemid 34026497)
122. Ferlay J., Shin H.-R., Bray F., Forman D., Mathers C., Parkin D. M., Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International Journal of Cancer 2010 127 12 2893 2917 2-s2.0-78049485263 10.1002/ijc.25516
123. Madigan M. P., Ziegler R. G., Benichou J., Byrne C., Hoover R. N., Proportion of breast cancer cases in the United States explained by well-established risk factors. Journal of the National Cancer Institute 1995 87 22 1681 1685 2-s2.0-0028856381
124. Guise T. A., Brufsky A., Coleman R. E., Understanding and optimizing bone health in breast cancer. Current Medical Research and Opinion 2010 26 supplement 3 3 20 2-s2.0-78349282653 10.1185/03007995.2010.533162
125. Pantel K., Alix-Panabières C., Circulating tumour cells in cancer patients: challenges and perspectives. Trends in Molecular Medicine 2010 16 9 398 406 2-s2.0-77956268304 10.1016/j.molmed.2010.07.001
126. Glass A. G., Lacey J. V. Jr., Carreon J. D., Hoover R. N., Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. Journal of the National Cancer Institute 2007 99 15 1152 1161 2-s2.0-34547816651 10.1093/jnci/djm059 (Pubitemid 47233065)
127. Qamri Z., Preet A., Nasser M. W., Bass C. E., Leone G., Barsky S. H., Ganju R. K., Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer. Molecular Cancer Therapeutics 2009 8 11 3117 3129 2-s2.0-70949091684 10.1158/1535-7163.MCT-09-0448
128. Caffarel M. M., Andradas C., Mira E., Pérez-Gómez E., Cerutti C., Moreno-Bueno G., Flores J. M., García-Real I., Palacios J., Mañes S., Guzmán M., Sánchez C., Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition. Molecular Cancer 2010 9, article 196 2-s2.0-77954789824 10.1186/1476-4598-9-196
129. 1 cannabinoid receptor are dependent on lipid rafts and regulated by anandamide in human breast cancer cells. FEBS Letters 2005 579 28 6343 6349 2-s2.0-27744562012 10.1016/j.febslet.2005.10.016 (Pubitemid 41612150)
130. Ligresti A., Moriello A. S., Starowicz K., Matias I., Pisanti S., de Petrocellis L., Laezza C., Portella G., Bifulco M., di Marzo V., Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. Journal of Pharmacology and Experimental Therapeutics 2006 318 3 1375 1387 2-s2.0-33747624175 10.1124/jpet.106.105247 (Pubitemid 44268348)
131. Bisogno T., Katayama K., Melck D., Ueda N., de Petrocellis L., Yamamoto S., di Marzo V., Biosynthesis and degradation of bioactive fatty acid amides in human breast cancer and rat pheochromocytoma cells-implications for cell proliferation and differentiation. European Journal of Biochemistry 1998 254 3 634 642 2-s2.0-0032526098 10.1046/j.1432-1327.1998.2540634.x (Pubitemid 28308116)
132. Takeda S., Yamaori S., Motoya E., Matsunaga T., Kimura T., Yamamoto I., Watanabe K., Δ9-tetrahydrocannabinol enhances MCF-7 cell proliferation via cannabinoid receptor-independent signaling. Toxicology 2008 245 1-2 141 146 2-s2.0-39249083222 10.1016/j.tox.2007.12.019
133. Ford L. A., Roelofs A. J., Anavi-Goffer S., Mowat L., Simpson D. G., Irving A. J., Rogers M. J., Rajnicek A. M., Ross R. A., A role for L- α -lysophosphatidylinositol and GPR55 in the modulation of migration, orientation and polarization of human breast cancer cells. British Journal of Pharmacology 2010 160 3 762 771 2-s2.0-77952627758 10.1111/j.1476-5381.2010.00743.x
134. Grimaldi C., Pisanti S., Laezza C., Malfitano A. M., Santoro A., Vitale M., Caruso M. G., Notarnicola M., Iacuzzo I., Portella G., di Marzo V., Bifulco M., Anandamide inhibits adhesion and migration of breast cancer cells. Experimental Cell Research 2006 312 4 363 373 2-s2.0-29144447456 10.1016/j.yexcr.2005.10.024 (Pubitemid 41804104)
135. McAllister S. D., Christian R. T., Horowitz M. P., Garcia A., Desprez P.-Y., Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells. Molecular Cancer Therapeutics 2007 6 11 2921 2927 2-s2.0-36749015683 10.1158/1535-7163.MCT-07-0371 (Pubitemid 350206770)
136. Huang G. Z., Woolley C. S., Estradiol acutely suppresses inhibition in the hippocampus through a sex-specific endocannabinoid and mGluR-dependent mechanism. Neuron 2012 74 5 801 808 10.1016/j.neuron.2012.03.035
137. Taylor A. H., Pringle J. H., Bell S. C., Al-Azzawi F., Specific inhibition of estrogen receptor alpha function by antisense oligodeoxyribonucleotides. Antisense and Nucleic Acid Drug Development 2001 11 4 219 231 2-s2.0-0034856928 (Pubitemid 32852881)
138. Taylor A. H., Al-Azzawi F., Pringle J. H., Bell S. C., Inhibition of endometrial carcinoma cell growth using antisense estrogen receptor oligodeoxyribonucleotides. Anticancer Research 2002 22 6 3993 4003 2-s2.0-0036875356 (Pubitemid 36134425)
139. Djulbegovic M., Beyth R. J., Neuberger M. M., Stoffs T. L., Vieweg J., Djulbegovic B., Dahm P., Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. British Medical Journal 2010 341, article c4543 2-s2.0-77957102886 10.1136/bmj.c4543
140. Schröder F. H., Hugosson J., Roobol M. J., Tammela T. L. J., Ciatto S., Nelen V., Kwiatkowski M., Lujan M., Lilja H., Zappa M., Denis L. J., Recker F., Määpttänen A. B., Bangma C. H., Aus G., Villers A., Rebillard X., van Kwast T. D., Blijenberg B. G., Moss S. M., de Koning H. J., Auvinen A., Screening and prostate-cancer mortality in a randomized european study. The New England Journal of Medicine 2009 360 13 1320 1328 2-s2.0-63249118690 10.1056/NEJMoa0810084
141. Ruiz L., Miguel A., Díaz-Laviada I., Δ9-tetrahydrocannabinol induces apoptosis in human prostate PC-3 cells via a receptor-independent mechanism. FEBS Letters 1999 458 3 400 404 2-s2.0-0032586054 10.1016/S0014-5793(99)01073-X (Pubitemid 29433843)
142. Brown I., Cascio M. G., Wahle K. W. J., Smoum R., Mechoulam R., Ross R. A., Pertwee R. G., Heys S. D., Cannabinoid receptor-dependent and -independent anti-proliferative effects of omega-3 ethanolamides in androgen receptor-positive and -negative prostate cancer cell lines. Carcinogenesis 2010 31 9 1584 1591 2-s2.0-77956278506 10.1093/carcin/bgq151
143. 1 receptor expression and regulation by IL-4. PLoS ONE 2010 5 8 2-s2.0-77957906635 10.1371/journal.pone.0012275 e12275
144. Pĩeiro R., Maffucci T., Falasca M., The putative cannabinoid receptor GPR55 defines a novel autocrine loop in cancer cell proliferation. Oncogene 2011 30 2 142 152 2-s2.0-78651383853 10.1038/onc.2010.417
145. Owerbach D., Rutter W. J., Cooke N. E., The prolactin gene is located on chromosome 6 in humans. Science 1981 212 4496 815 816 2-s2.0-0019827906 (Pubitemid 11069382)
146. Kelly P. A., Djiane J., Postel-Vinay M.-C., Edery M., The prolactin/growth hormone receptor family. Endocrine Reviews 1991 12 3 235 251 2-s2.0-0026096241
147. Mimeault M., Pommery N., Wattez N., Bailly C., Hénichart J.-P., Anti-proliferative and apoptotic effects of anandamide in human prostatic cancer cell lines: implication of epidermal growth factor receptor down-regulation and ceramide production. Prostate 2003 56 1 1 12 2-s2.0-0038751939 10.1002/pros.10190 (Pubitemid 36613150)
148. Sarfaraz S., Afaq F., Adhami V. M., Malik A., Mukhtar H., Cannabinoid receptor agonist-induced apoptosis of human prostate cancer cells LNCaP proceeds through sustained activation of ERK1/2 leading to G 1 cell cycle arrest. Journal of Biological Chemistry 2006 281 51 39480 39491 2-s2.0-33845973763 10.1074/jbc.M603495200 (Pubitemid 46041908)
149. Amant F., Moerman P., Neven P., Timmerman D., van Limbergen E., Vergote I., Endometrial cancer. The Lancet 2005 366 9484 491 505 2-s2.0-23444461364 10.1016/S0140-6736(05)67063-8 (Pubitemid 41111699)
150. Cancer Research UK, Cancer Statistics 2011
151. Dossus L., Allen N., Kaaks R., Bakken K., Lund E., Tjonneland A., Olsen A., Overvad K., Clavel-Chapelon F., Fournier A., Chabbert-Buffet N., Boeing H., Schütze M., Trichopoulou A., Trichopoulos D., Lagiou P., Palli D., Krogh V., Tumino R., Vineis P., Mattiello A., Bueno-de-Mesquita H. B., Charlotte Onland-Moret N., Peeters P. H. M., Dumeaux V., Redondo M.-L., Duell E., Sanchez-Cantalejo E., Arriola L., Chirlaque M.-D., Ardanaz E., Manjer J., Borgquist S., Lukanova A., Lundin E., Khaw K.-T., Wareham N., Key T., Chajes V., Rinaldi S., Slimani N., Mouw T., Gallo V., Riboli E., Reproductive risk factors and endometrial cancer: the European prospective investigation into cancer and nutrition. International Journal of Cancer 2010 127 2 442 451 2-s2.0-77953707725 10.1002/ijc.25050
152. Kaaks R., Lukanova A., Kurzer M. S., Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiology Biomarkers & Prevention 2002 11 12 1531 1543 2-s2.0-0036907571 (Pubitemid 36020003)
153. Modugno F., Ness R. B., Chen C., Weiss N. S., Inflammation and endometrial cancer: a hypothesis. Cancer Epidemiology Biomarkers & Prevention 2005 14 12 2840 2847 2-s2.0-30344435634 10.1158/1055-9965.EPI-05-0493 (Pubitemid 43068813)
154. Doherty J. A., Cushing-Haugen K. L., Saltzman B. S., Voigt L. F., Hill D. A., Beresford S. A., Chen C., Weiss N. S., Long-term use of postmenopausal estrogen and progestin hormone therapies and the risk of endometrial cancer. American Journal of Obstetrics and Gynecology 2007 197 2 139.e1 139.e7 2-s2.0-34547572363 10.1016/j.ajog.2007.01.019 (Pubitemid 47198156)
155. Halis G., Arici A., Endometriosis and inflammation in infertility. Annals of the New York Academy of Sciences 2004 1034 300 315 2-s2.0-14944361655 10.1196/annals.1335.032 (Pubitemid 40362369)
156. Chegini N., Proinflammatory and profibrotic mediators: principal effectors of leiomyoma development as a fibrotic disorder. Seminars in Reproductive Medicine 2010 28 3 180 203 2-s2.0-77951590255 10.1055/s-0030- 1251476
157. Soper D. E., Pelvic inflammatory disease. Obstetrics and Gynecology 2010 116 2, part 1 419 428 2-s2.0-77955156393 10.1097/AOG.0b013e3181e92c54
158. Walker C. L., Stewart E. A., Uterine fibroids: the elephant in the room. Science 2005 308 5728 1589 1592 2-s2.0-20444389034 10.1126/science.1112063 (Pubitemid 40807499)
159. Vlahos N. F., Economopoulos K. P., Fotiou S., Endometriosis, in vitro fertilisation and the risk of gynaecological malignancies, including ovarian and breast cancer. Best Practice & Research 2010 24 1 39 50 2-s2.0-76449118670 10.1016/j.bpobgyn.2009.08.004
160. Lax S. F., Pizer E. S., Ronnett B. M., Kurman R. J., Comparison of estrogen and progesterone receptor, Ki-67, and p53 immunoreactivity in uterine endometrioid carcinoma and endometrioid carcinoma with squamous, mucinous, secretory, and ciliated cell differentiation. Human Pathology 1998 29 9 924 931 2-s2.0-0031715566 10.1016/S0046-8177(98)90197-6 (Pubitemid 28422040)
161. Oehler M. K., Brand A., Wain G. V., Molecular genetics and endometrial cancer. Journal of the British Menopause Society 2003 9 1 27 31 2-s2.0-0037344863 10.1258/136218003100322116 (Pubitemid 36362090)
162. 2 and its ligand 2-arachidonoylglycerol are elevated in endometrial carcinoma. Endocrinology 2010 151 3 921 928 2-s2.0-77149124893 10.1210/en.2009-0883
163. Guzmán M., Sánchez C., Galve-Roperh I., Cannabinoids and cell fate. Pharmacology & Therapeutics 2002 95 2 175 184 2-s2.0-0036669523 10.1016/S0163-7258(02)00256-5 (Pubitemid 35232135)
164. 2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. Blood 2002 100 2 627 634 2-s2.0-0037100312 10.1182/blood-2002-01-0098 (Pubitemid 34761128)